Literature DB >> 14694033

Profile of cognitive progression in early Huntington's disease.

A K Ho1, B J Sahakian, R G Brown, R A Barker, J R Hodges, M-N Ané, J Snowden, J Thompson, T Esmonde, R Gentry, J W Moore, T Bodner.   

Abstract

OBJECTIVE: To examine the pattern of cognitive decline in early Huntington's disease (HD).
METHODS: The authors studied 61 patients with mild to moderate HD who had at least three annual neuropsychological assessments using the Core Assessment Program for Intracerebral Transplantation in Huntington's Disease short battery. A subset of 34 patients had additional neuropsychological tests, and another subset of 21 patients was assessed annually on the Cambridge Neuropsychological Test Automated Battery. Neuropsychological measures that changed significantly over time were submitted to a multiple analysis of covariance to explore associations with demographic and neurologic indices.
RESULTS: Patients showed a progressive impairment in attention, executive function, and immediate memory, with timed tests of psychomotor skill being particularly sensitive to decline. In contrast, general cognition, semantic memory, and delayed recall memory were relatively unaffected.
CONCLUSION: The profile of cognitive performance shows selective and progressive dysfunction of attention and executive function in patients with mild to moderate HD, consistent with frontostriatal pathology at this stage of disease.

Entities:  

Mesh:

Year:  2003        PMID: 14694033     DOI: 10.1212/01.wnl.0000098878.47789.bd

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  59 in total

1.  The application of rules in morphology, syntax and number processing: a case of selective deficit of procedural or executive mechanisms?

Authors:  Joël Macoir; Marion Fossard; Jean-Luc Nespoulous; Jean-François Demonet; Anne-Catherine Bachoud-Lévi
Journal:  Neurocase       Date:  2010-05-05       Impact factor: 0.881

2.  Huntington's disease: changes in saccades and hand-tapping over 3 years.

Authors:  Chrystalina A Antoniades; Zheyu Xu; Sarah L Mason; R H S Carpenter; Roger A Barker
Journal:  J Neurol       Date:  2010-06-29       Impact factor: 4.849

Review 3.  Brain imaging and cognitive dysfunctions in Huntington's disease.

Authors:  Alonso Montoya; Bruce H Price; Matthew Menear; Martin Lepage
Journal:  J Psychiatry Neurosci       Date:  2006-01       Impact factor: 6.186

Review 4.  Neuropsychological assessment of dementia.

Authors:  David P Salmon; Mark W Bondi
Journal:  Annu Rev Psychol       Date:  2009       Impact factor: 24.137

5.  Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice.

Authors:  Danielle A Simmons; Christopher S Rex; Linda Palmer; Vijay Pandyarajan; Vadim Fedulov; Christine M Gall; Gary Lynch
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-05       Impact factor: 11.205

Review 6.  Progress and prospects for genetic modification of nonhuman primate models in biomedical research.

Authors:  Anthony W S Chan
Journal:  ILAR J       Date:  2013

Review 7.  Cell therapy in Huntington's disease.

Authors:  Stephen B Dunnett; Anne E Rosser
Journal:  NeuroRx       Date:  2004-10

8.  The BACHD Rat Model of Huntington Disease Shows Signs of Fronto-Striatal Dysfunction in Two Operant Conditioning Tests of Short-Term Memory.

Authors:  Erik Karl Håkan Clemensson; Laura Emily Clemensson; Olaf Riess; Huu Phuc Nguyen
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

9.  Understanding patient-reported outcome measures in Huntington disease: at what point is cognitive impairment related to poor measurement reliability?

Authors:  N E Carlozzi; S Schilling; A L Kratz; J S Paulsen; S Frank; J C Stout
Journal:  Qual Life Res       Date:  2018-06-16       Impact factor: 4.147

10.  Measuring executive dysfunction longitudinally and in relation to genetic burden, brain volumetrics, and depression in prodromal Huntington disease.

Authors:  Kathryn V Papp; Peter J Snyder; James A Mills; Kevin Duff; Holly J Westervelt; Jeffrey D Long; Spencer Lourens; Jane S Paulsen
Journal:  Arch Clin Neuropsychol       Date:  2012-12-16       Impact factor: 2.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.